[1]尹文惠,李素霞,董春晓,等.穿透性角膜移植术后发生继发性青光眼的影响因素及治疗方法[J].眼科新进展,2020,40(3):230-234.[doi:10.13389/j.cnki.rao.2020.0054]
　YIN Wenhui,LI Suxia,DONG Chunxiao,et al.Influential factors and effect analysis of treatment for secondary glaucoma after penetrating keratoplasty[J].Recent Advances in Ophthalmology,2020,40(3):230-234.[doi:10.13389/j.cnki.rao.2020.0054]
点击复制

穿透性角膜移植术后发生继发性青光眼的影响因素及治疗方法/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年3期
页码:
230-234
栏目:
应用研究
出版日期:
2020-03-05

文章信息/Info

Title:
Influential factors and effect analysis of treatment for secondary glaucoma after penetrating keratoplasty
作者:
尹文惠; 李素霞; 董春晓; 冯莉娟; 刘敏; 王欣; 史伟云
266071　山东省青岛市，青岛大学医学部（尹文惠，冯莉娟）；250021　山东省济南市，山东第一医科大学（山东省医学科学院），山东省眼科研究所，山东省眼科学重点实验室-省部共建国家重点实验室培育基地，山东省眼科医院（李素霞，董春晓，刘敏，王欣，史伟云）
Author(s):
YIN Wenhui1; LI Suxia2; DONG Chunxiao2; FENG Lijuan1; LIU Min2; WANG Xin2; SHI Weiyun2
1.Medical College of Qingdao University,Qingdao 266071,Shandong Province,China2.Shandong Eye Hospital,State Key Laboratory Cultivation Base,Shandong Provincial Key Laboratory of Ophthalmology,Shandong Eye Institute,Shandong First Medical University & Shandong Academy of Medical Sciences,Jinan 250021,Shandong Province,China
关键词:
穿透性角膜移植术; 高眼压; 青光眼
Keywords:
penetrating keratoplasty;  intraocular hypertension;  glaucoma
分类号:
R779.65
DOI:
10.13389/j.cnki.rao.2020.0054
文献标志码:
A
摘要:
目的　探讨穿透性角膜移植术（penetrating keratoplasty,PKP）后发生继发性青光眼的影响因素和治疗方法。方法　回顾性临床研究。收集2016年1月至2018年11月在山东省眼科医院行PKP术后继发青光眼患者60例（60眼），根据发病时间、发作次数、术前有无青光眼病史对术后发生继发性青光眼患者进行分组。采用t检验、Mann-Whitney U检验或χ2检验比较组间的临床资料，采用Logistic回归分析术后发生早期青光眼、术后青光眼多次发作的危险因素。结果　PKP术后继发性青光眼患者60例（60眼），随访（16.0±11.0）个月，总发生率为10.5%（60/573）。术后早期青光眼发病率为6.1%（35/573），主要诱因包括术后严重前房炎症及虹膜粘连19例，浅前房5例，其他11例。35例患者中药物治疗21例，联合手术治疗14例，以小梁切除术为主，共8例，最终眼压控制率为71.4%（25/35）。术后晚期青光眼发生率为4.4%（25/573），激素类药物诱发15例，周边虹膜前粘连6例，其他4例。单纯药物治疗21例，眼压控制率72%（18/25）。不同发病时间组间前房积脓、青光眼治疗方式比较，差异均有统计学意义（χ2=6.898，P=0.009；χ2=4.000，P=0.046）；术前有青光眼者术后青光眼发作频繁，差异有统计学意义（χ2=5.137,P=0.023）。术前严重的前房积脓是术后早期继发性青光眼发生的危险因素，术前青光眼病史是继发性青光眼多次发作的危险因素。结论　严重的角膜感染、青光眼病史、糖皮质激素药物使用是PKP术后青光眼发生的影响因素。PKP治疗的不同时期继发性青光眼防治重点不同，单纯药物和手术治疗对眼压控制均有效且无明显差异。
Abstract:
Objective　To investigate the influencing factors and treatment outcomes of secondary glaucoma after penetrating keratoplasty (PKP).Methods　A retrospective clinical study was conducted on 60 cases (60 eyes) with secondary glaucoma occurred after PKP at the Shandong Eye Hospital from January 2016 to November 2018. All patients were grouped according to the time of onset, the number of episodes and the history of glaucoma. Clinical data were compared with t test, Mann-Whitney U test or χ test among groups. Logistic regression analysis was used to analyze the risk factors of having early glaucoma and multiple attacks of glaucoma after operation.Results　Sixty patients (60 eyes) with secondary glaucoma were included, and followed up for (16.0±11.0) months. The total incidence of secondary glaucoma was 10.5% (60/573). The incidence of early postoperative glaucoma was 6.1% (35/573), and the main causes included severe anterior chamber inflammation and iris adhesion in 19 cases and shallow anterior chamber in 5 cases and other factors in 11 cases. Among 35 patients,21 patients underwent drug therapy, 14 patients underwent combined surgery, and trabeculectomy was the main operative method, which was performed in 8 patients. The final intraocular pressure control rate was 71.4%(25/35). The incidence of late postoperative glaucoma was 4.4% (25/573), induced by hormonal drugs in 15 cases, by peripheral anterior synechia in 6 cases and other factors in 4 cases. Twenty one patients were treated with drug alone, and the intraocular pressure control rate was 72% (18/25). There were significant differences in anterior chamber empyema and the treatment of glaucoma between the different onset time groups (χ2=6.898, P=0.009;χ2=4.000,P=0.046). Preoperative glaucoma patients have more frequent glaucoma episodes after operation, and the difference was statistically significant (χ2=5.137, P=0.023). Severe anterior chamber empyema was a risk factor for secondary glaucoma in the early postoperative period. The history of preoperative glaucoma was a risk factor for frequent episodes of secondary glaucoma.Conclusion　Severe corneal infection, history of glaucoma, glucocorticoid drugs are the influencing factors of post-PKP glaucoma. The prevention and treatment of secondary glaucoma in different periods of PKP treatment were different. Simple drug treatment and operation were both effective for control of intraocular pressure, and had no significant difference.

参考文献/References:

［1］　CHIEN A M,SCHMIDT C M,COHEN E J,RAJPAL R K,SPERBER L T D,RAPUANO C J,et al.Glaucoma in the immediate postoperative period after penetrating keratoplasty［J］.Am J Ophthalmol,1993,115(6):711-714.
［2］　HUBER K K,MAIER A K,KLAMANN M K,ROTTLER J,OZLUGEDIK S,ROSENBAUM K,et al.Glaucoma in penetrating keratoplasty:risk factors,management and outcome［J］.Graefes Arch Clin Exp Ophthalmol,2013,251(1):105-116.
［3］　谢立信，史伟云，刘敬，李绍伟，曹景.穿透性角膜移植术后继发性青光眼的临床分析［J］.中华眼科杂志,2000，36(2):35-37.
XIE L X,SHI W Y,LIU J,LI S W,CAO J.Clinical analysis of secondary glaucoma after penetrating keratoplasty ［J］.Chin J Ophthalmol,2000，36(2):35-37.
［4］　HADDADIN R I,CHODOSH J.Corneal transplantation and glaucoma［J］.Semin Ophthalmol,2014,29(5-6):380-396.
［5］　KIRKNESS C M,FICKER L A.Risk factors for the development of postkeratoplasty glaucoma［J］.Cornea,1992,11(5):427-432.
［6］　DADA T,AGGARWAL A,KB M,VANATHI M,CHOUDHARY S,GUPTA V,et al.Post-penetrating keratoplasty glaucoma［J］.Indian J Ophthalmol,2008,56(4):269-277.
［7］　RAHMAN I,CARLEY F,HILLARBY C,BRAHMA A,TULLO A B.Penetrating keratoplasty:indications,outcomes,and complications［J］.Eye(Lond),2009,23(6):1288-1294.
［8］　SANDHU S,PETSOGLOU C,GRIGG J,VEILLARD A S.Elevated intraocular pressure in patients undergoing penetrating keratoplasty and descemet stripping endothelial keratoplasty［J］.J Glaucoma,2016,25(4):390-396.
［9］　张文佳,胡竹林.穿透角膜移植术后继发青光眼的研究现状［J］.中华实验眼科杂志,2008,26(12):952-956.
ZHANG W J,HU Z L.Investigation of secondary glaucoma following penetrating keratoplasty ［J］.Chin J Exp Ophthalmol，2008,26(12):952-956.
［10］　王艳青,王新,刘平.穿透性角膜移植术后高眼压的临床分析［J］.眼科新进展,2013,33(12):1181-1183.
WANG Y Q,WANG X，LIU P.Clinical analysis of high intraocular pressure after penetrating keratoplasty ［J］.Rec Adv Ophthalmol，2013,33(12):1181-1183.
［11］　刘平,王艳青,王新.穿透性角膜移植术后疗效分析80例［J］.眼科新进展,2008,28(7):545-546.
LIU P,WANG Y Q,WANG X.Clinical analysis of penetrating keratoplasty in 80 cases ［J］.Rec Adv Ophthalmol,2008,28(7):545-546.
［12］　徐娜娜,赵桂秋,王青,车成业,姜楠,李翠.伴高眼压的感染性角膜溃疡患者行穿透角膜溃疡患者行穿透性角膜移植术的疗效分析［J］.中华临床医师杂志(电子版),2012,6(14):4061-4063.
XU N N,ZHAO G Q,WANG Q,CHE C Y,JIANG N,LI C.Therapeutic effect of penetrating keratoplasty in patients with infective corneal ulcer with high intraocular pressure［J］.Chin J Clinic(Electron Edit),2012,6(14):4061-4063.
［13］　WU S,XU J.Incidence and risk factors for post-penetrating keratoplasty glaucoma:A systematic review and meta-analysis［J］.PLoS One,2017,12(4):e0176261.
［14］　FAIK O O,BLUMENTHAL E Z,JOSEPH F,PABRAHAM S.Risk factors and incidence of ocular hypertension after penetrating keratoplasty［J］.J Glaucoma,2014,23(9):599-605.
［15］　AYYALA R S.Penetrating keratoplasty and glaucoma［J］.Surv Ophthalmol,2000,45(2):1972-1979.
［16］　BANITT M,LEE R K.Management of patients with combined glaucoma and corneal transplant surgery［J］.Eye(Lond),2009,23(10):1972-1979.
［17］　STEWART R M K,JONES M N A,BATTERBURY M,TOLE D,LARKIN D F P,KAYE S B.Effect of glaucoma on corneal graft survival according to indication for penetrating keratoplasty［J］.Am J Ophthalmol,2011,151(2):257-262.
［18］　GREENLEE E C,KWON Y H.Graft failure:III.Glaucoma escalation after penetrating keratoplasty［J］.Int Ophthalmol,2008,28(3):191-207.
［19］ 　孙亚杰，李爱朋，潘志强，骆非，邹留河.免疫抑制剂在穿透性角膜移植术后应用的系统评价［J］.中华眼科杂志,2010,46(12):1122-1127.
SUN Y J,LI A P,PAN Z Q,LUO F,ZOU L H.Systematic review of penetrating keratoplasty rejection treated by immunosuppressants ［J］.Chin J Ophthalmol,2010,46(12):1122-1127.
［20］　BORDERIE V M,LORIAUT P,BOUHERAOUA N,NORDMANN J P.Incidence of intraocular pressure elevation and glaucoma after lamellar versus full-thickness penetrating keratoplasty［J］.Ophthalmology,2016,123(7):1428-1434.
［21］　KARESH J W,NIRANKARI V S.Factors associated with glaucoma after penetrating keratoplasty［J］.Am J Ophthalmol,1983,96(2):160-164.
［22］　WARD M S,GOINS K M,GREINER M A,KITZMANN A S,SUTPHIN J E,ALWARD W L M,et al.Graft survival versus glaucoma treatment after penetrating or descemet stripping automated endothelial keratoplasty［J］.Cornea,2014,33(8):785-789.
［23］　郝静华,骆非,闫超,潘志强.穿透性角膜移植术后继发青光眼的疗效分析［J］.眼科,2014，23(6):392-397.
HAO J H,LUO F,YAN C,PAN Z Q.Effect analysis of treatment for post-penetrating keratoplasty glaucoma ［J］.Ophthalmol CHN，2014，23(6):392-397.
［24］　AL-TORBAK A.Graft survival and glaucoma outcome after simultaneous penetrating keratoplasty and ahmed glaucoma valve implant［J］.Cornea,2003,22(3):194-197.

相似文献/References:

[1]李雪 刁玉梅 李兵.IL-12及 Th1/Th2细胞因子在 IL-10修饰的树突状细胞诱导大鼠角膜移植免疫耐受中的作用[J].眼科新进展,2012,32(5):000.
[2]杨铮 陈彬川 周瑞雅.玻璃体手术后高眼压及其处理[J].眼科新进展,2012,32(11):000.
[3]梁静 万新顺.川芎嗪对慢性高眼压大鼠视网膜神经节细胞凋亡的影响[J].眼科新进展,2013,33(8):000.
[4]韩莎莎 王婷 孟丽丽 史伟云.深板层及穿透性角膜移植术治疗圆锥角膜术后屈光状态的比较[J].眼科新进展,2013,33(9):000.
[5]李星仪 黄薇岚 袁进 林晓蕾 陈家祺.穿透性角膜移植手术治疗棘阿米巴性角膜炎的临床研究[J].眼科新进展,2012,32(1):000.
[6]李兰 杨文艳 李云川.穿透性角膜移植术后继发性青光眼的影响因素及治疗[J].眼科新进展,2012,32(2):000.
[7]刘鑫 苏冠方 王晨光 祝伟.玻璃体切割联合眼内填充术后眼压升高的相关因素分析及治疗[J].眼科新进展,2013,33(11):000.
[8]宋五德,梁章海. 不同前房深度急性闭角型青光眼持续高眼压患者的手术疗效分析[J].眼科新进展,2014,34(4):366.[doi:10.13389/j.cnki.rao.2014.0100]
[9]周林,姚进.增殖性糖尿病性视网膜病变玻璃体切割术后高眼压的研究[J].眼科新进展,2015,35(1):074.[doi:10.13389/j.cnki.rao.2015.0021]
　ZHOU Lin,YAO Jin.Study on secondary ocular hypertension after vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(3):074.[doi:10.13389/j.cnki.rao.2015.0021]
[10]申晓丽,樊宁,赵军,等.超声微泡造影剂联合鼠神经生长因子对高眼压兔视神经损害的保护作用[J].眼科新进展,2016,36(4):301.[doi:10.13389/j.cnki.rao.2016.0082]
　SHEN Xiao-Li,FAN Ning,ZHAO Jun,et al.Neuroprotective effects of ultrasonic microbubbles and mouse nerve growth factor on rabbit hypertension optic nerve damage[J].Recent Advances in Ophthalmology,2016,36(3):301.[doi:10.13389/j.cnki.rao.2016.0082]
[11]王艳青 王新 刘平.穿透性角膜移植术后高眼压的临床分析[J].眼科新进展,2013,33(12):000.

备注/Memo

备注/Memo:
国家自然科学基金项目（编号：81530027、81470611）；山东泰山学者计划项目（编号：20150215）
更新日期/Last Update: 2020-03-05